AXNX Stock Price, Chart, Stats & News

Axonics, Inc.
Save
3.63B
Market cap
–
Current P/E
–
Forward P/E
AXNX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 74.94% |
Operating margin | -7.11% |
Pretax margin | -2.39% |
Net margin | -1.66% |
Effective tax rate | 30.38% |
ROA | -0.85% |
ROE | -1.01% |
D/E | 0.04x |
Interest coverage ratio | – |
AXNX valuation
P/E | – |
P/S | 9.90x |
P/B | 5.46x |
P/CF | -1728.08x |
P/FCF | -651.77x |
P/OCF | -1728.08x |
PEG | 3.04x |
EV multiple | 476.52x |
About
Axonics, Inc. is a medical device firm that focuses on developing and bringing to market sacral neuromodulation (SNM) solutions. These advanced SNM systems are designed to address a range of medical conditions, such as overactive bladder (including urinary urge incontinence and frequent urges to urinate), alongside fecal incontinence and non-obstructive urinary retention. The company's flagship rechargeable SNM System, known as r-SNM, operates by delivering gentle electrical impulses to specific sacral nerves, aiming to restore regular communication between the brain and the bladder or bowel, thereby lessening the symptoms of their dysfunction.
Similar securities
Based on sector and market capitalization
Report issue











